Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSX:SVA)

0.1550 -0.0100 (-6.06%)
Streaming Delayed Price Updated: 3:17 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 302,755
Open 0.1700
Bid (Size) 0.1500 (780)
Ask (Size) 0.1550 (540)
Prev. Close 0.1650
Today's Range 0.1550 - 0.1700
52wk Range 0.1500 - 0.3500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SAIF Partners Sends Open Letter to Sinovac Shareholders Outlining Current Board’s Failure to Act in the Interests of Shareholders
From SAIF Partners IV L.P.,
Via Business Wire
Sinovac Clears Legal Hurdle In Control Battle, Moves Forward With $55 Dividend
A U.S. court denied an emergency injunction sought by dissenting investors, while a separate case in Antigua could unlock an additional $11 per share if disputed PIPE shares are invalidated. 
Via Stocktwits

Performance

YTD
-32.6%
-32.6%
1 Month
-8.8%
-8.8%
3 Month
N/A
N/A
6 Month
-29.5%
-29.5%
1 Year
-54.4%
-54.4%

More News

Read More
Prime Success Issues Statement on New York State Court Decision Confirming Our Rights as Sinovac Shareholders – Including Right to Vote at Upcoming Special Meeting
From Prime Success L.P.
Via Business Wire
SINOVAC Announces New Board Member
From Sinovac Biotech Ltd.
Via Business Wire
Sernova Announces Key New Executive Appointments
Via TheNewswire.com
Prime Success Sets the Record Straight Regarding Continued False and Misleading Statements from Sinovac Biotech’s Current Board
From Prime Success L.P.
Via Business Wire
SAIF Partners Files Definitive Proxy Materials in Connection with Sinovac Biotech 2025 Special Meeting of Shareholders; Nominates Ten Highly Qualified Director Candidates to the Board
From SAIF Partners IV L.P.
Via Business Wire
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success’ New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
From SINOVAC Biotech Ltd.
Via Business Wire
Prime Success Responds to Sinovac Biotech’s False and Misleading Claims
From Prime Success L.P.
Via Business Wire
SINOVAC’s Board of Directors Issues a Letter to Shareholders Outlining Clear Pathway to Restore Fairness and Deliver Value to All Shareholders
From Sinovac Biotech Ltd.
Via Business Wire
Vivo Capital Issues Letter to Sinovac Biotech Shareholders Addressing the Company’s False and Misleading Claims
From Vivo Capital
Via Business Wire
Prime Success Sends Letter to Sinovac Biotech Shareholders
From Prime Success L.P.
Via Business Wire
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2024 Annual Report
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Board Issues Letter to Shareholders to Set the Record Straight on the Hostile Actions and False Claims by Vivo Capital
From Sinovac Biotech Ltd.
Via Business Wire
Vivo Capital Files Lawsuits to Protect Sinovac Shareholders from the New Board’s Value Destructive Actions
From Vivo Capital
Via Business Wire
SINOVAC Announces Decision to Declare Cash Dividend
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces New Board Member and Chairman of the Audit Committee
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Announces New Board Pursuant to Privy Council Judgment and Order
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Issues Statement Regarding Privy Council Judgment
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Initiated a Phase III Clinical Trial on Bivalent Vaccine Against Hand Foot and Mouth Disease (HFMD)
From Sinovac Biotech Ltd.
Via Business Wire
Sernova to Present at the 2024 Cell & Gene Meeting on the Mesa
Via NewMediaWire
SINOVAC Reports Unaudited First Half of 2024 Financial Results
From Sinovac Biotech Ltd.
Via Business Wire
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
From Sinovac Biotech Ltd.
Via Business Wire
Sernova Provides Positive Clinical and Platform Portfolio Update
Via TheNewswire.com

Frequently Asked Questions

Is SVA publicly traded?
Yes, SVA is publicly traded.
What exchange does SVA trade on?
SVA trades on the Toronto Stock Exchange
What is the ticker symbol for SVA?
The ticker symbol for SVA is SVA on the Toronto Stock Exchange
What is the current price of SVA?
The current price of SVA is 0.1550
When was SVA last traded?
The last trade of SVA was at 06/30/25 03:17 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.